Constellation NewEnergy

Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company specializing in the field of epigenetics to discover and develop novel therapeutics for patients with cancer and other serious diseases. The company's research focuses on small molecule inhibitors that target epigenetic regulators, such as BET proteins and EZH2, which play critical roles in gene expression and disease progression. Its lead product candidate, pelabresib (CPI-0610), is a selective BET inhibitor currently in Phase 3 clinical development for the treatment of myelofibrosis. Constellation was acquired by MorphoSys in 2021 for approximately $1.7 billion and subsequently became part of Novartis following Novartis's acquisition of MorphoSys in 2024.